Evolution of treatment targets in Crohn's disease

被引：4
作者：
White, Jonathan R. [1 ,2 ,3 ]
Jairath, Vipul [4 ,5 ]
Moran, Gordon W. [1 ,2 ,3 ]
机构：
[1] Nottingham Univ Hosp NHS Trust, Nottingham Biomed Res Ctr, Natl Inst Hlth Res, Nottingham, England
[2] Univ Nottingham, Nottingham, England
[3] Univ Nottingham, Nottingham Digest Dis Ctr, Nottingham, England
[4] Western Univ, Div Gastroenterol, Dept Med, London, ON, Canada
[5] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada
来源：
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY | 2019年 / 38-39卷
关键词：
Crohn's disease; Treatment targets; Patient reported outcomes; Clinician reported activity indices; Biomarkers; Endoscopy; Imaging; Histology; INFLAMMATORY-BOWEL-DISEASE; PATIENT-REPORTED OUTCOMES; C-REACTIVE PROTEIN; POST-HOC ANALYSIS; QUALITY-OF-LIFE; FECAL CALPROTECTIN; ULCERATIVE-COLITIS; ACTIVITY INDEX; LEMANN INDEX; MAINTENANCE THERAPY;
D O I：
10.1016/j.bpg.2019.02.001
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Crohn's disease is a chronic relapsing and remitting inflammatory disorder of the gastrointestinal tract, associated with significantly morbidity due to both symptoms and complications that have a considerable detrimental impact on a patient's quality of life. An early treat to target approach with disease modifying agents has been shown to significantly improve long term outcomes, demonstrated by a number of therapeutic targets in a number of modalities. This review will outline the current treatment targets and measures of disease burden in Crohn's disease. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页数：9
相关论文
共 105 条
  • [51] A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
    Khanna, R.
    Zou, G.
    D'Haens, G.
    Feagan, B. G.
    Sandborn, W. J.
    Vandervoort, M. K.
    Rolleri, R. L.
    Bortey, E.
    Paterson, C.
    Forbes, W. P.
    Levesque, B. G.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (01) : 77 - 86
  • [52] Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
    Khanna, Reena
    Bressler, Brian
    Levesque, Barrett G.
    Zou, Guangyong
    Stitt, Larry W.
    Greenberg, Gordon R.
    Panaccione, Remo
    Bitton, Alain
    Pare, Pierre
    Vermeire, Severine
    D'Haens, Geert
    MacIntosh, Donald
    Sandborn, William J.
    Donner, Allan
    Vandervoort, Margaret K.
    Morris, Joan C.
    Feagan, Brian G.
    [J]. LANCET, 2015, 386 (10006) : 1825 - 1834
  • [53] Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
    Kiss, L. S.
    Szamosi, T.
    Molnar, T.
    Miheller, P.
    Lakatos, L.
    Vincze, A.
    Palatka, K.
    Barta, Z.
    Gasztonyi, B.
    Salamon, A.
    Horvath, G.
    Toth, G. T.
    Farkas, K.
    Banai, J.
    Tulassay, Z.
    Nagy, F.
    Szenes, M.
    Veres, G.
    Lovasz, B. D.
    Vegh, Z.
    Golovics, P. A.
    Szathmari, M.
    Papp, M.
    Lakatos, P. L.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (08) : 911 - 922
  • [54] Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) Symptom Scales in Subjects With Inflammatory Bowel Diseases
    Kochar, Bharati
    Martin, Christopher F.
    Kappelman, Michael D.
    Spiegel, Brennan M.
    Chen, Wenli
    Sandler, Robert S.
    Long, Millie D.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (01) : 72 - 79
  • [55] RESPONSE TO DRUG-THERAPY IN CROHNS-DISEASE - EVALUATION BY RECTAL BIOPSY AND MUCOSAL CELL COUNTS
    KORELITZ, BI
    SOMMERS, SC
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1984, 6 (02) : 123 - 127
  • [56] High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: A marker for patient classification?
    Lajos Sandor Kiss
    Maria Papp
    Barbara Dorottya Lovasz
    Zsuzsanna Vegh
    Petra Anna Golovics
    Eszter Janka
    Eva Varga
    Miklos Szathmari
    Peter Laszlo Lakatos
    [J]. INFLAMMATORY BOWEL DISEASES, 2012, 18 (09) : 1647 - 1654
  • [57] Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial
    Lémann, M
    Mary, JY
    Duclos, B
    Veyrac, M
    Dupas, JL
    Delchier, JC
    Laharie, D
    Moreau, J
    Cadiot, G
    Picon, L
    Bourreille, A
    Sobahni, I
    Colombel, JF
    [J]. GASTROENTEROLOGY, 2006, 130 (04) : 1054 - 1061
  • [58] A randomized, douuble-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine
    Lémann, M
    Mary, JY
    Colombel, JF
    Duclos, B
    Soule, JC
    Lerebours, E
    Modigliani, R
    Bouhnik, Y
    [J]. GASTROENTEROLOGY, 2005, 128 (07) : 1812 - 1818
  • [59] Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted county, Minnesota, 1940-2000
    Loftus, Conor G.
    Loftus, Edward V., Jr.
    Harmsen, W. Scott
    Zinsmeister, Alan R.
    Tremaine, William J.
    Melton, L. Joseph, III
    Sandborn, William J.
    [J]. INFLAMMATORY BOWEL DISEASES, 2007, 13 (03) : 254 - 261
  • [60] Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
    Louis, Edouard
    Mary, Jean-Yves
    Vernier-Massouille, Gwenola
    Grimaud, Jean-Charles
    Bouhnik, Yoram
    Laharie, David
    Dupas, Jean-Louis
    Pillant, Helene
    Picon, Laurence
    Veyrac, Michel
    Flamant, Mathurin
    Savoye, Guillaume
    Jian, Raymond
    Devos, Martine
    Porcher, Raphael
    Paintaud, Gilles
    Piver, Eric
    Colombel, Jean-Frederic
    Lemann, Marc
    [J]. GASTROENTEROLOGY, 2012, 142 (01) : 63 - U201
12345678910